| Title |
Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
|
|---|---|
| Published in |
Clinical Pharmacokinetics, February 2014
|
| DOI | 10.1007/s40262-014-0137-2 |
| Pubmed ID | |
| Authors |
Huixin Yu, Neeltje Steeghs, Cynthia M. Nijenhuis, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema |
| Abstract |
There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM) in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between exposure and response (efficacy/toxicity) have been established for several TKIs. For example, the pharmacokinetic targets for efficacy of imatinib, sunitinib and pazopanib have been defined as trough plasma concentrations (Ctrough) of >1,000, >50 and >20,000 ng/mL for selected indications, respectively. Dose adjustment based on pharmacokinetic targets could therefore increase response rates and duration. Furthermore, with appropriate target concentrations defined, excessive side effects in patients using the current fixed dosing strategy may be prevented. This review provides a practical guideline for TDM for the currently approved TKIs at 28 February 2013. The focus of this article is on the elaboration of exposure and response relationships of TKIs with proposed pharmacokinetic targets, mainly Ctrough, and further on the interpretation of the pharmacokinetic targets with recommendations for dose titrations. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 4 | 50% |
| Japan | 1 | 13% |
| Unknown | 3 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Indonesia | 1 | <1% |
| Czechia | 1 | <1% |
| Unknown | 113 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 36 | 31% |
| Researcher | 19 | 16% |
| Student > Master | 8 | 7% |
| Student > Bachelor | 8 | 7% |
| Student > Postgraduate | 7 | 6% |
| Other | 20 | 17% |
| Unknown | 19 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 35 | 30% |
| Medicine and Dentistry | 28 | 24% |
| Agricultural and Biological Sciences | 10 | 9% |
| Chemistry | 6 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Other | 7 | 6% |
| Unknown | 29 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 August 2015.
All research outputs
#5,507,801
of 22,745,803 outputs
Outputs from Clinical Pharmacokinetics
#436
of 1,481 outputs
Outputs of similar age
#51,566
of 220,969 outputs
Outputs of similar age from Clinical Pharmacokinetics
#3
of 15 outputs
Altmetric has tracked 22,745,803 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,481 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 220,969 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.